CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (NASDAQ: ZLCS) today reported financial results for the fourth quarter and year ended December 31, 2011.
“In 2011, we made significant progress in advancing our product candidates in clinical development, including Synavive, Z160 and Z944,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “During 2012, we will see the results of those studies and make important decisions on next steps. This is evident with the successful reformulation of Z160, in which we have achieved the consistent exposure levels necessary to evaluate its efficacy in a Phase 2 clinical study for neuropathic pain later this year.”
